Corporate Magazine 2012 - Boehringer Ingelheim

Research with passionIn 2012, we employed an average of 7,492 people at our R&D sites. A total of almostEUR 2.8 billion was invested in the research and development of new medicines forhumans. R&D expenditure in the business area Prescription Medicines corresponds+ 22.5% of its net sales. Boehringer Ingelheim thereby once again increased its researchand development activities compared to the previous year and once more exceedsthe industry average.In Human Pharmaceuticals we are presented with a well-filled pipeline of competitivesubstances, mainly in oncology, diabetes, asthma and hepatitis C. And wehave a tight series of planned launches of product innovations and thereby continuedgrowth potential.In Animal Health the focus is on the research and development of innovative vaccines,primarily for protecting livestock and companion animals, as well as on pharmaceuticalproducts. Boehringer Ingelheim invested around EUR 115 million in 2012,roughly 11% of total Animal Health sales, in researching and developing new productsand in building up a global network of new R&D sites. An average 450 employeesworked at Animal Health’s R&D sites in the USA, Germany, Mexico, Chinaand Japan in 2012, researching new active ingredients for animal health and forward-lookingtherapeutic solutions.Future challengesOur own research and development will also be of paramount priority in the future.On the basis of promising product innovations in our research and developmentpipeline, we are laying the foundations for Boehringer Ingelheim’s continuous,organic, economic growth.We will be in the position of being able to, and having to, invest in launching substancesfrom our well-filled product pipeline in the therapeutic areas oncology,diabetes, asthma and hepatitis C. After entering the diabetes market in 2011, weexpect to enter oncology market in 2013 and extend our respiratory portfolio. Thesubstances from the advanced pipeline, foremost afatinib in lung cancer and tiotropiumor olodaterol in respiratory diseases, have the potential to be ready for themarket as early as in 2013 as well as in the next few years.14Boehringer Ingelheim annual report 2012